{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:42:05Z","timestamp":1770154925027,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.leukres.2023.107376","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T12:07:47Z","timestamp":1693310867000},"page":"107376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5172-6539","authenticated-orcid":false,"given":"Davidson","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-0478","authenticated-orcid":false,"given":"Qianghua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojgan","family":"Zarif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9857-6440","authenticated-orcid":false,"given":"Entsar","family":"Eladl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuihong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Tierens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Wing Tony","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3106-2776","authenticated-orcid":false,"given":"Hong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2023.107376_bib1","doi-asserted-by":"crossref","unstructured":"Su L., Shi Y.Y., Liu Z.Y., Gao S.J. Acute myeloid leukemia with CEBPA mutations: current progress and future directions. Front. Oncol. [Internet]. 2022 Feb 1 [cited 2023 Apr 12];12. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/35178345\/\u3009.","DOI":"10.3389\/fonc.2022.806137"},{"key":"10.1016\/j.leukres.2023.107376_bib2","doi-asserted-by":"crossref","unstructured":"Ohlsson E., Schuster M.B., Hasemann M., Porse B.T. The multifaceted functions of C\/EBP\u03b1 in normal and malignant haematopoiesis. Leukemia [Internet]. 2016 Apr 1 [cited 2023 Apr 12];30(4):767\u201375. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/26601784\/\u3009.","DOI":"10.1038\/leu.2015.324"},{"key":"10.1016\/j.leukres.2023.107376_bib3","doi-asserted-by":"crossref","unstructured":"Wouters B.J., L\u00f6wenberg B., Erpelinck-Verschueren C.A.J., Van Putten W.L.J., Valk P.J.M., Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood [Internet]. 2009 Mar 26 [cited 2023 May 27];113(13):3088\u201391. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/19171880\/\u3009.","DOI":"10.1182\/blood-2008-09-179895"},{"key":"10.1016\/j.leukres.2023.107376_bib4","doi-asserted-by":"crossref","unstructured":"Pabst T., Eyholzer M., Fos J., Mueller B.U. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br. J. Cancer [Internet]. 2009 Apr 21 [cited 2023 May 27];100(8):1343\u20136. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/19277035\/\u3009.","DOI":"10.1038\/sj.bjc.6604977"},{"key":"10.1016\/j.leukres.2023.107376_bib5","doi-asserted-by":"crossref","unstructured":"Green C.L., Koo K.K., Hills R.K., Burnett A.K., Linch D.C., Gale R.E. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J. Clin. Oncol. [Internet]. 2010 Jun 1 [cited 2023 May 27];28(16):2739\u201347. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/20439648\/\u3009.","DOI":"10.1200\/JCO.2009.26.2501"},{"key":"10.1016\/j.leukres.2023.107376_bib6","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2010.031336","article-title":"Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia","author":"Hollink","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107376_bib7","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107376_bib8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020009652","article-title":"CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children\u2019s Oncology Group","author":"Tarlock","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107376_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021004292","article-title":"Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia","author":"Wakita","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107376_bib10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020009680","article-title":"CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome","author":"Taube","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107376_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107376_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107376_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107376_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase","author":"Gupta","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107376_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000044","article-title":"Clinical utility of next-generation sequencing in the management of myeloproliferative neoplasms: a single-center experience","author":"Alduaij","year":"2018","journal-title":"HemaSphere"},{"key":"10.1016\/j.leukres.2023.107376_bib16","doi-asserted-by":"crossref","DOI":"10.5858\/arpa.2016-0547-RA","article-title":"Integration of technical, bioinformatic, and variant assessment approaches in the validation of a targeted next-generation sequencing panel for myeloid malignancies","author":"Thomas","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.leukres.2023.107376_bib17","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107376_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","author":"Tazi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2023.107376_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26812","article-title":"Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia","author":"Falini","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107376_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","author":"Shimony","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107376_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-023-01909-w","article-title":"AML classification in the year 2023: How to avoid a Babylonian confusion of languages","author":"Huber","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107376_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.229","article-title":"C\/EBP\u03b1 deregulation as a paradigm for leukemogenesis","author":"Pulikkan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107376_bib23","article-title":"Effects of short indels on protein structure and function in human genomes","author":"Lin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.leukres.2023.107376_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6807-10-24","article-title":"Systematic analysis of short internal indels and their impact on protein folding","author":"Kim","year":"2010","journal-title":"BMC Struct. Biol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:17Z","timestamp":1758935057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":24,"alternative-id":["S0145212623006410"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107376","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107376"}}